Abstract |
A two-part study was done to assess the value of human fibroblast interferon (IFN-beta) in the treatment of condylomata acuminata. The first part was an open study of different IFN-beta preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-beta. In the double-blind placebo section 22 patients were given injections of 2 X 10(6) units IFN-beta or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-beta group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-beta and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5')oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-beta produce a systemic response.
|
Authors | A Schonfeld, S Nitke, A Schattner, D Wallach, M Crespi, T Hahn, H Levavi, O Yarden, J Shoham, T Doerner |
Journal | Lancet (London, England)
(Lancet)
Vol. 1
Issue 8385
Pg. 1038-42
(May 12 1984)
ISSN: 0140-6736 [Print] England |
PMID | 6143975
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Interferon Type I
- 2',5'-Oligoadenylate Synthetase
|
Topics |
- 2',5'-Oligoadenylate Synthetase
(blood)
- Adolescent
- Adult
- Animals
- Clinical Trials as Topic
- Condylomata Acuminata
(therapy)
- Double-Blind Method
- Female
- Genital Neoplasms, Female
(therapy)
- Genital Neoplasms, Male
(therapy)
- Humans
- Injections, Intramuscular
- Interferon Type I
(administration & dosage)
- Leukocytes
(enzymology)
- Male
- Papillomaviridae
(growth & development)
- Random Allocation
- Tumor Virus Infections
(therapy)
- Virus Replication
(drug effects)
|